Laparoscopic sleeve gastrectomy leads to rapid improvement of glucose tolerance and insulin secretion with enhanced glucagon-like peptide (GLP-1) secretion

Diabetology International

Volumn 1, Issue 2, 2010, Pages 99-103

  Ugi, Satoshi ^a   Yamamoto, Hiroshi ^a   Kusunoki, Chisato ^a   Kamo, Azusa ^a   Ikeda, Kazuhiro ^a   Hashimoto, Tetsuya ^a   Nishio, Yoshihiko ^a   Kasama, Kazunori ^b   Tani, Toru ^a   Kashiwagi, Atsunori ^a   Maegawa, Hiroshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Hand Surgery Center   (Japan)

Author keywords

Ghrelin; GLP 1; Sleeve gastrectomy

Indexed keywords

GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; CASE REPORT; GASTRECTOMY; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; LAPAROSCOPIC SLEEVE GASTRECTOMY; LAPAROSCOPIC SURGERY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

EID: 84862872785     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-010-0011-x     Document Type: Article

References (31)

1. Vetter ML, Cardillo S, Rickels MR, et al. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009; 150: 94-103.
2. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292: 1724-37.
3. Regan JP, Inabnet WB, Gagner M, et al. Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg. 2003; 13: 861-4.
4. Deitel M, Crosby RD, Gagner M. The first international consensus summit for sleeve gastrectomy (SG), New York City, October 25-27, 2007. Obes Surg. 2008; 18: 487-96.
5. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008; 247: 401-7.
6. Silecchia G, Boru C, Pecchia A, et al. Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on co-morbidities in super-obese high-risk patients. Obes Surg. 2006; 16: 1138-44.
7. Kasama K, Tagaya N, Kanahira E, et al. Has laparoscopic bariatric surgery been accepted in Japan? The experience of a single surgeon. Obes Surg. 2008; 18: 1473-8.
8. Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008; 18: 1077-82.
9. Langer FB, Reza Hoda MA, Bohdjalian A, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg. 2005; 15: 1024-9.
10. Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009; 250: 234-41.
11. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22: 1462-70.
12. Laferrere B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93: 2479-85.
13. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000; 141: 4255-61.
14. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007; 87: 1409-39.
15. Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (second of two parts). N Eng J Med. 1981; 304: 1575-80.
16. Hare KJ, Vilsboll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010; 59: 1765-70.
17. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001; 50: 609-13.
18. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001; 86: 3717-23.
19. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentration in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008; 57: 678-87.
20. Lee S, Yabe D, Nohtomi K, et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J. 2010; 57: 119-26.
21. Guldstrand M, Ahren B, Naslund E, et al. Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. Diabetes Obes Metab. 2009; 11: 1027-33.
22. Melissas J, Koukouraki S, Askoxylakis J, et al. Sleeve gastrectomy: a restrictive procedure? Obes Surg. 2007; 17: 57-62.
23. Braghetto I, Davanzo C, Korn O, et al. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg. 2009; 19: 1515-21.
24. Yamamoto H, Mori T, Tsuchihashi H, et al. A possible role of GLP-1 in the pathophysiology of early dumping syndrome. Dig Dis Sci. 2005; 50: 2263-7.
25. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132: 2131-57.
26. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 2003; 46: 798-801.
27. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91: 301-7.
28. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001; 409: 194-8.
29. Yada T, Dezaki K, Sone H, et al. Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential. Curr Diabetes Rev. 2008; 4: 18-23.
30. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001; 86: 5083-6.
31. Dezaki K, Sone H, Koizumi M, et al. Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance. Diabetes. 2006; 55: 3486-93.